🇺🇸 FDA
Patent

US 11174232

Substituted heterocyclyl derivatives as CDK inhibitors

granted A61KA61K31/415A61K31/4155

Quick answer

US patent 11174232 (Substituted heterocyclyl derivatives as CDK inhibitors) held by Aurigene Discovery Technologies Limited expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aurigene Discovery Technologies Limited
Grant date
Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/415, A61K31/4155, A61K31/416, A61K31/4439